% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Betts:141501,
author = {Betts, Matthew J and Kirilina, Evgeniya and Otaduy, Maria C
G and Ivanov, Dimo and Acosta-Cabronero, Julio and
Callaghan, Martina F and Lambert, Christian and
Cardenas-Blanco, Arturo and Pine, Kerrin and Passamonti,
Luca and Loane, Clare and Keuken, Max C and Trujillo, Paula
and Lüsebrink, Falk and Mattern, Hendrik and Liu, Kathy Y
and Priovoulos, Nikos and Fliessbach, Klaus and Dahl, Martin
J and Maaß, Anne and Madelung, Christopher F and Meder,
David and Ehrenberg, Alexander J and Speck, Oliver and
Weiskopf, Nikolaus and Dolan, Raymond and Inglis, Ben and
Tosun, Duygu and Morawski, Markus and Zucca, Fabio A and
Siebner, Hartwig R and Mather, Mara and Uludag, Kamil and
Heinsen, Helmut and Poser, Benedikt A and Howard, Robert and
Zecca, Luigi and Rowe, James B and Grinberg, Lea T and
Jacobs, Heidi I L and Düzel, Emrah and Hämmerer, Dorothea},
title = {{L}ocus coeruleus imaging as a biomarker for noradrenergic
dysfunction in neurodegenerative diseases.},
journal = {Brain},
volume = {142},
number = {9},
issn = {0006-8950},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DZNE-2020-07825},
pages = {2558-2571},
year = {2019},
abstract = {Pathological alterations to the locus coeruleus, the major
source of noradrenaline in the brain, are histologically
evident in early stages of neurodegenerative diseases. Novel
MRI approaches now provide an opportunity to quantify
structural features of the locus coeruleus in vivo during
disease progression. In combination with neuropathological
biomarkers, in vivo locus coeruleus imaging could help to
understand the contribution of locus coeruleus
neurodegeneration to clinical and pathological
manifestations in Alzheimer's disease, atypical
neurodegenerative dementias and Parkinson's disease.
Moreover, as the functional sensitivity of the noradrenergic
system is likely to change with disease progression, in vivo
measures of locus coeruleus integrity could provide new
pathophysiological insights into cognitive and behavioural
symptoms. Locus coeruleus imaging also holds the promise to
stratify patients into clinical trials according to
noradrenergic dysfunction. In this article, we present a
consensus on how non-invasive in vivo assessment of locus
coeruleus integrity can be used for clinical research in
neurodegenerative diseases. We outline the next steps for in
vivo, post-mortem and clinical studies that can lay the
groundwork to evaluate the potential of locus coeruleus
imaging as a biomarker for neurodegenerative diseases.},
keywords = {Biomarkers: metabolism / Humans / Locus Coeruleus:
diagnostic imaging / Locus Coeruleus: metabolism / Magnetic
Resonance Imaging: methods / Neurodegenerative Diseases:
diagnostic imaging / Neurodegenerative Diseases: metabolism
/ Norepinephrine: metabolism},
cin = {AG Speck / AG Düzel / Patient Studies Bonn},
ddc = {610},
cid = {I:(DE-2719)1340009 / I:(DE-2719)5000006 /
I:(DE-2719)1011101},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31327002},
pmc = {pmc:PMC6736046},
doi = {10.1093/brain/awz193},
url = {https://pub.dzne.de/record/141501},
}